Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Clinical Study of Legend Biotech BCMA-chimeric Antigen Receptor Technology in Treating Relapsed/Refractory (R/R) Multiple Myeloma Patients

Next Previous
X
Search
Trial Profile

A Clinical Study of Legend Biotech BCMA-chimeric Antigen Receptor Technology in Treating Relapsed/Refractory (R/R) Multiple Myeloma Patients

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 01 Aug 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ciltacabtagene autoleucel (Primary) ; Cyclophosphamide; Fludarabine
  • Indications Multiple myeloma
  • Focus Adverse reactions; First in man; Proof of concept
  • Acronyms LEGEND-2
  • Sponsors Nanjing Legend Biotech

    • Most Recent Events

    • 15 Jun 2023 Results assessing the efficacy and safety of LCAR-B38M after at least 5 years of follow-up in LEGEND-2 presented at the 28th Congress of the European Haematology Association
    • 08 Jun 2023 Planned End Date changed from 31 Dec 2021 to 31 Dec 2023.
    • 08 Jun 2023 Planned primary completion date changed from 31 Dec 2021 to 31 Dec 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top